Business Wire

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral ...

New data show brain-volume preservation correlates with patient outcomesLong-term clinical data indicate 77.4 weeks (17.8 months) time saved with ...
Business Wire

Arrakis Therapeutics Announces Oral Presentation Describing RNA-targeted Small Molecule to Treat Myotonic Dystrophy at MDA Conference 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that ...
Rochester Institute of Technology

Oral Presentations

For presentations scheduled prior to 1:00 PM, please go to the SHED Atrium between 8:00 and 8:30 AM and load your final presentation. For presentations scheduled after 1:00 PM, please go to the SHED ...

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, ...

NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant ...

NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 – NMD Pharma A/S, a ...